Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. A new stem cell ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Co. (WFC), Abbott Laboratories (ABT) and American Express Co. (AXP), as well as two micro-cap stocks ...

Discover the top 10 large-cap stocks rated Buy across Seeking Alpha, Wall Street, and analyst systems, featuring strong ...